PROMETRIUM (progesterone) by Fresenius Kabi is clinical pharmacology prometrium capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. First approved in 1998.
Drug data last refreshed 2d ago
PROMETRIUM is an oral micronized progesterone capsule approved in 1998 for multiple gynecological indications including infertility, contraception, preterm birth prevention, menopause symptom management, and use in IVF protocols. It is chemically identical to naturally occurring ovarian progesterone and works by binding to progesterone receptors to support reproductive and endocrine function. The micronization technology enhances oral bioavailability, with peak serum concentrations achieved within 1.5–2.3 hours depending on dose.
Product is approaching end-of-life with generic entry imminent; commercial teams should anticipate workforce rightsizing and transition focus to life-cycle management and retention strategies.
CLINICAL PHARMACOLOGY PROMETRIUM Capsules are an oral dosage form of micronized progesterone which is chemically identical to progesterone of ovarian origin. The oral bioavailability of progesterone is increased through micronization. Pharmacokinetics A. Absorption After oral administration of…
Worked on PROMETRIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Progesterone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert
Exogenous Progesterone as Ovulation Trigger
Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PROMETRIUM offers limited growth trajectory but provides solid foundational experience in women's health commercialization and multi-indication franchise management. As the product approaches end-of-life, career progression depends on ability to transition to growth-stage assets within female health or broader endocrinology portfolios.